The US Food and Drug Administration (FDA) has granted approval for Takeda’s ENTYVIO subcutaneous (SC) administration as a maintenance therapy to treat adults with moderately to severely active ...

If you are worried about using this medicine, speak to your doctor or pharmacist. Entyvio contains the active ingredient vedolizumab. Entyvio is used to treat the signs and symptoms of moderate to ...

Takeda's new biologic therapy, Entyvio, has been approved in the US for ulcerative colitis and Crohn's disease. The drug is entering a hugely competitive marketplace, dominated by the TNF blocker ...

More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerative colitis. The new ...

ENTYVIO is a prescription biologic infusion drug, indicated for patients with moderate to severe ulcerative colitis (UC) and Crohn's Disease (CD).